Alzamend Neuro has completed the clinical portion of a Phase 2 trial testing AL001, an investigational formulation of lithium…
Articles by Marisa Horak, MS
The U.S. Food and Drug Administration (FDA) has agreed to review a request to convert Leqembi’s (lecanemab) accelerated approval…
The U.S. Food and Drug Administration (FDA) will consider brexpiprazole to treat agitation in people with Alzheimer’s disease. The…
Treatment with lecanemab (BAN2401), an experimental amyloid-targeting antibody, significantly slowed the progression of dementia symptoms among people with early…
Trametinib, an oral medication approved to treat certain cancers, improved cognition and neuronal health in a mouse model of…
The U.S. Food and Drug Administration (FDA) has agreed to review an application from Eisai seeking accelerated approval of…
Hoth Therapeutics and Washington University have agreed to extend preclinical research into HT-ALZ, Hoth’s experimental therapy for Alzheimer’s disease.
Alzheimer’s patients given the experimental tau-targeting therapy HMTM in a Phase 3 clinical trial experienced a substantially slower…
The U.S. Food and Drug Administration (FDA) has granted marketing permission to a new test that checks for amyloid plaques…
Biogen is eliminating corporate infrastructure that had been put in place to support sales of Aduhelm (aducanumab) in…